



## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Stephen M. COUTTS et al.

Serial No.: 09/752,533

Filing Date: December 29, 2000

For: CONJUGATES OF CHEMICALLY

DEFINED NON-POLYMERIC

VALENCY PLATFORM MOLECULES

AND BIOLOGICALLY ACTIVE MOLECULES (AS AMENDED)

Examiner: To Be Assigned

Group Art Unit: 1653

RECEIVED

AUG 0 1 2001

**TECH CENTER 1600/2900** 

## PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY UNDER 37 C.F.R. § 3.71

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

La Jolla Pharmaceutical Company, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Randolph Ted Apple (Reg No. 36,429)
Sanjay S. Bagade (Reg No. 42,280)
Erwin J. Basinski (Reg No. 34,773)
Richard R. Batt (Reg No. 43,485)
Vincent J. Belusko (Reg No. 30,820)
Kimberly A. Bolin (Reg No. 44,546)
Tyler S. Brown (Reg No. 36,465)
A. Randall Camacho (Reg No. 46,595)
Robert K. Cerpa (Reg No. 39,933)
Alex Chartove (Reg No. 31,942)
Thomas E. Ciotti (Reg No. 21,013)
Matthew M. D'Amore (Reg No. 42,457)
Peter Davis (Reg No. 36,119)
Carolyn A. Favorito (Reg No. 39,183)

Hector Gallegos (Reg No. 40,614)

Laurie A. Axford (Reg No. 35,053)
Joseph Barrera (Reg No. 44,522)
Shantanu Basu (Reg No. 43,318)
Frank P. Becking (Reg No. 42,309)
Jonathan Bockman (Reg No. 45,640)
Barry E. Bretschneider (Reg No. 28,055)
Nicholas Buffinger (Reg No. 39,124)
Mark R. Carter (Reg No. 39,131)
Peng Chen (Reg No. 43,543)
Thomas Chuang (Reg No. 44,616)
Cara M. Coburn (Reg No. 46,631)
Raj S. Davé (Reg No. 42,465)
Stephen C. Durant (Reg No. 31,506)
David L. Fehrman (Reg No. 28,600)
Thomas George (Reg No. 45,740)

Debra J. Glaister (Reg No. 33,888) Johney U. Han (Reg No. 45,565) Alan S. Hodes (Reg No. 38,185) Peter Hsieh (Reg No. 44,780) Madeline I. Johnston (Reg No. 36,174) Parisa Joriani (Reg No. 46,813) Richard C. Kim (Reg No. 40,046) Kawai Lau (Reg No. 44,461) Michael J. Mauriel (Reg No. 44,226) Philip A. Morin (Reg No. P-45,926) Martin M. Noonen (Reg No. 44,264) Paul J. Riley (Reg No. 38,596) Terri Shieh-Newton (Reg No. 47,081) Kevin R. Spivak (Reg No. 43,148) Michael R. Ward (Reg No. 38,651) Todd W. Wight (Reg No. 45,218) David T. Yang (Reg No. 44,415) George C. Yu (Reg No. 44,418)

Kenneth R. Glick (Reg No. 28,612) Douglas G. Hodder (Reg No. 41,840) Charles D. Holland (Reg No. 35,196) Wayne Jaeschke, Jr. (Reg No. 38,503) Richard D. Jordan (Reg No. 33,519) Ararat Kapouytian (Reg No. 40,044) Cameron A. King (Reg No. 41,897) Rimas T. Lukas (Reg No. 46,451) Gladys H. Monroy (Reg No. 32,430) Kate H. Murashige (Reg No. 29,959) Catherine M. Polizzi (Reg No. 40,130) Debra A. Shetka (Reg No. 33,309) Rebecca Shortle (Reg No. 47,083) Stanley H. Thompson (Reg No. 45,160) E. Thomas Wheelock (Reg No. 28,825) Frank Wu (Reg No. 41,386) Peter J. Yim (Reg No. 44,417) Karen R. Zachow (Reg No. 46,332)

all of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Please direct all written communications relative to this application to:

Madeline I. Johnston Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-1018

Please direct all telephone communications to Madeline I. Johnston at (650) 813-5840.

LA JOLLA PHARMACEUTICAL COMPANY a Delaware corporation

Dated: July 20, 2001

Name: Andrew Wiseman

Title: Director of Business Development Address: 6455 Nancy Ridge Drive

San Diego, CA 92121





AUG 0 1 2001 PTO/SB/96 (10-92)

Fin	- CONT				AUG 0 1 2001 110/30/20 (10-72)
Docket No. 252312005704					
In the application of: Serial No.: Filed: For:			Stephen M. COUTTS et al. 09/752,533 December 29, 2000 CONJUGATES OF CHEMICALLY I MOLECULES AND BIOLOGICALL	DEFINED NON-F	COLYMERIC VALENCY PLATFORM ECULES (AS AMENDED)
La Jolla Pharmaceutical Company, a Delaware corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:					
Α. Ι	X	An assign in the Pate	ment from the inventor(s) of the patent ent and Trademark Office at Reel 6827,	application identi Frame 0662, or for	fied above. The assignment was recorded which a copy thereof is attached.
OR					
В. І		A chain of below:	f title from the inventor(s) of the patent a	application identif	led above, to the current assignee as shown
•	1.	From: * To: * The document is attached		demark Office at F	Reel *, Frame *, or for which a copy thereof
:	2.	From: * To: * The documents attached		demark Office at I	Reel *, Frame *, or for which a copy thereof
	3.	From: * To: * The document is attached		demark Office at I	Reel *, Frame *, or for which a copy thereof
		Additiona	al documents in the chain of title are liste	ed on a supplemen	tal sheet.
		Copies of	assignments or other documents in the	chain of title are a	ttached.
The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.					
The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.					
I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.					
Dated: July 20, voo/  Name: Andrew Wiseman					
	,			3	rector of Business Development

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE